[Clinical use of factor IX concentrates]
[Article in
German]
- PMID: 1215901
Item in Clipboard
[Clinical use of factor IX concentrates]
[Article in
German]
Schweiz Med Wochenschr.
.
Abstract
Factor IX concentrates are of paramount importance in the treatment of hemophilia B. Growing reports of thromboembolic complications and of disseminated intravascular coagulation, coupled with the danger of hepatitis transmission, suggest that the concentrates should be primarily reserved for the treatment of hemophilia B. Concise guidelines for treatment are presented.
Similar articles
-
Current management of hemophilia B.Hematol Oncol Clin North Am. 1993 Dec;7(6):1269-80. Hematol Oncol Clin North Am. 1993. PMID: 8294316 Review.
-
Thrombogenicity associated with factor IX complex concentrates.Semin Hematol. 1991 Jul;28(3 Suppl 6):3-5. Semin Hematol. 1991. PMID: 1780767 Review. No abstract available.
-
Factor IX thrombogenicity: in vivo effects on coagulation activation and a case report of disseminated intravascular coagulation.Thromb Haemost. 1982 Aug 24;48(1):76-7. Thromb Haemost. 1982. PMID: 7135346
-
Substitution treatment of hemophilia a and b.Schweiz Med Wochenschr. 1975 Jun 14;105(24):783-4. Schweiz Med Wochenschr. 1975. PMID: 1145162 English.
-
Factor IX concentrates for clinical use.Semin Thromb Hemost. 1993;19(1):25-36. doi: 10.1055/s-2007-994003. Semin Thromb Hemost. 1993. PMID: 8456321 Review. No abstract available.